Open AccessCardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase
Author(s) -
Sandra Frankenreiter,
Dieter Groneberg,
Anna Kuret,
Thomas Krieg,
Peter Ruth,
Andreas Friebe,
Robert Łukowski
Publication year - 2018
Publication title -
cardiovascular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.774
H-Index - 219
eISSN - 1755-3245
pISSN - 0008-6363
DOI - 10.1093/cvr/cvy039
Subject(s) - cardioprotection , soluble guanylyl cyclase , nitric oxide , cyclic guanosine monophosphate , guanylate cyclase , guanosine , gucy1a3 , guanosine monophosphate , chemistry , pharmacology , gucy1b3 , medicine , cardiology , ischemia , biochemistry , guanylate cyclase 2c , nucleotide , gene
It has been suggested that the nitric oxide-sensitive guanylyl cyclase (NO-GC)/cyclic guanosine monophosphate (cGMP)-dependent signalling pathway affords protection against cardiac damage during acute myocardial infarction (AMI). It is, however, not clear whether the NO-GC/cGMP system confers its favourable effects through a mechanism located in cardiomyocytes (CMs). The aim of this study was to evaluate the infarct-limiting effects of the endogenous NO-GC in CMs in vivo.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom